Pre-market: Relief Therapeutics RLF.SW CHF2.89 on 13 Mar 2026: bounce watch

RLF.SW stock opens pre-market at CHF2.89, setting up an oversold bounce after a recent low near CHF1.65. Volume is elevated at 66,704.00 shares versus an average of 41,210.00, signalling short-term buyer interest. Relief Therapeutics (RLF.SW) trades on SIX in Switzerland and shows a 52-week range of CHF1.65–CHF4.59. We examine why this bounce matters, the fundamentals, technical setup, and the risks ahead.

RLF.SW stock market snapshot and the oversold bounce

The immediate fact: pre-market price sits at CHF2.89 with a day low of CHF2.80 and high of CHF3.00. Relative volume at 1.62 reflects above-average trading and supports an oversold bounce thesis. The stock has recovered 7.25% over three months but remains down 27.15% year-on-year, leaving room for mean-reversion if catalysts appear.

Fundamentals and valuation for RLF.SW stock

Relief Therapeutics reports EPS -1.36 and a negative PE of -2.12, reflecting development-stage losses. Market cap is CHF36.28M and book value per share is CHF2.60, giving a PB ratio near 1.11. Cash per share stands at CHF0.99 and current ratio is 4.05, which supports short-term runway while R&D continues.

Meyka AI rates RLF.SW with a score out of 100

Meyka AI rates RLF.SW with a score out of 100: 64.76 / 100, Grade B, Suggestion HOLD. This grade factors in S&P 500 and sector comparison, financial growth, key metrics, forecasts, and analyst consensus. These grades are informational only and not financial advice.

Technical setup, volume and short-term triggers for RLF.SW stock

Short-term technicals show price near the 50-day average (CHF2.91) and above the 200-day average (CHF2.61), a neutral-to-bullish context for a bounce. Intraday volume of 66,704.00 versus average 41,210.00 signals demand. A close above CHF3.00 with follow-through could confirm the oversold bounce trade.

Catalysts, trials and sector context affecting RLF.SW stock

Relief’s pipeline, including RLF-100 (aviptadil) and ACER-001, drives clinical catalysts. Upcoming earnings announcement is scheduled for 08 Apr 2026, which could move the stock. Healthcare sector peers trade at an average PE near 29.52, leaving the biotech name priced for outcomes and risk.

Risk management and a practical oversold bounce strategy

Risk is high: negative margins, clinical trial outcomes, and thin free-float can amplify moves. For traders we suggest scaled entries and stop-loss placement near the prior swing low (CHF1.65). Use position sizing to limit downside and target partial exits at CHF3.50 and CHF4.59 if momentum resumes.

Final Thoughts

Key takeaways on RLF.SW stock: Relief Therapeutics trades pre-market at CHF2.89 with elevated volume and a short-term oversold bounce setup. Fundamentals show a development-stage profile with EPS -1.36, a PB near 1.11, and cash per share around CHF0.99, which supports operations. Meyka AI’s forecast model projects a three-year target of CHF3.18, implying an upside of 10.36% from the current price; forecasts are model-based projections and not guarantees. Traders should weigh upcoming clinical catalysts and the April earnings date, use tight risk controls, and consider the stock a speculative bounce candidate rather than a core holding. For more data and live updates visit our Meyka AI stock page and Relief Therapeutics’ site for filings and pipeline details.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.